Epcoritamab

HEMATOLOGY · 年度盘点 2026.07 血液肿瘤只能靠化疗？ 从双抗到体内CAR-T 血液肿瘤的靶向革命 淋巴瘤 · 白血病 · 骨髓瘤 · 热门靶点 · 2/3期临床进展 · 国内在研格局 血液淋巴系统肿瘤 2024—2026 靶向免疫 📦 6 Parts + Conclusion 👉 滑动 PART 01 淋巴瘤 双抗崛起 PART 02 CLL/BTK 迭代降解 PART 03 急性白血病 menin时代 PART 04 骨髓瘤 BCMA前移 PART 05 细胞治疗 体内生成 PART /// 写在最后 清醒与展望 血液肿瘤已从化疗时代切换到“靶向+免疫”的多元精准时代 双抗前移 · BTK/BCL-2迭代 · menin开创 · CAR-T体内生成 血液淋巴系统肿瘤是创新药研发最活跃的领域之一。据GLOBOCAN 2022统计，全球非霍奇金淋巴瘤（NHL）年新发病例约55万例、白血病约49万例、多发性骨髓瘤（MM）约19万例、霍奇金淋巴瘤（HL）约8万例；中国淋巴瘤年新发病例约10万例，且发病率持续上升。与实体瘤不同，血液肿瘤的治疗范式已从化疗时代快速切换到“靶向小分子（BTK/BCL-2/menin/FLT3）+单抗双抗+ADC+CAR-T”的多元免疫精准时代。 2024—2026年，这一领域呈现出四条清晰的主线：一是双特异性抗体从末线向二线乃至一线前移，重塑淋巴瘤治疗格局；二是BTK抑制剂、BCL-2抑制剂完成代际迭代，国产创新药跻身全球第一梯队；三是menin抑制剂的开创性获批让急性白血病首次拥有分子分型驱动的口服靶向药；四是CAR-T从“体外制备”迈向“体内生成”，国产CAR-T已有8款获批上市。本文按病种梳理热门靶点、关键研究数据及国内企业在研项目。 01 PART 淋巴瘤：双特异性抗体崛起，一线格局持续演变 LYMPHOMA · BISPECIFIC ANTIBODIES RISE 1. 弥漫大B细胞淋巴瘤（DLBCL）：双抗前移与监管教训 一线方面，维泊妥珠单抗联合R-CHP（POLARIX研究）已取代沿用二十年的R-CHOP成为中高危DLBCL新标准。复发难治阶段，CD20×CD3双特异性抗体（格菲妥单抗、艾可瑞妥单抗、奥德罗奈昔单抗）相继获批三线治疗，其中前两款已在中国上市。2024—2026年的两个关键III期颇具戏剧性： CASE 01STARGLO：阳性数据不等于监管获批 格菲妥单抗+GemOx 对 R-GemOx（不适合移植的二线DLBCL）：死亡风险降低41%（HR=0.59），2年随访中位OS未达到对13.5个月，发表于《柳叶刀》。该方案已在35个以上国家获批。然而FDA于2025年5月召开肿瘤药物咨询委员会（ODAC），以8:1认定该研究人群（美国患者仅占9%、亚洲占48%）不适用于美国人群，2025年7月发出完整回复函（CRL）拒绝其二线适应症——试验人群的代表性成为全球多中心研究新的“硬指标”。 CASE 02ECHELON-3：为CAR-T不可及人群提供选择 维布妥昔单抗+来那度胺+利妥昔单抗 对 R2（不适合移植或CAR-T的复发难治大B细胞淋巴瘤）：中位OS 13.8个月对8.5个月（HR=0.63），ORR 64.3%对41.5%，2025年2月获FDA批准，为CAR-T不可及人群提供了有效选择。 2. 惰性B细胞淋巴瘤：去化疗方案确立 inMIND（他法西他单抗+来那度胺+利妥昔单抗，R/R滤泡性淋巴瘤）：548例随机对照，中位PFS 22.4个月对13.9个月（HR=0.43），2025年6月获FDA批准，为二线提供了首个无化疗方案。 EPCORE FL-1（艾可瑞妥单抗+R² 对 R²）：中位PFS未达到对11.7个月（HR=0.21，进展或死亡风险降低79%），ORR 95%对79%，CR率83%对50%，并观察到OS改善信号（HR=0.38）；2026年5月获NMPA批准，成为艾可瑞妥单抗在中国的首个适应症。 CAR-T进入惰性淋巴瘤：利司扑兰注射液（liso-cel）基于TRANSCEND-FL研究（ORR 95.7%）2024年5月获FDA批准用于三线及以上FL；莫妥珠单抗（CD20×CD3）亦已在中国获批用于三线FL。 3. 霍奇金淋巴瘤：PD-1+AVD改写一线 S1826研究（纳武利尤单抗+AVD 对 维布妥昔单抗+AVD，初治晚期经典霍奇金淋巴瘤，994例，含12岁以上青少年）：2年PFS率92%对83%（HR=0.45），且神经病变、粒缺发热发生率更低，发表于《新英格兰医学杂志》（2024），被视为晚期cHL一线的历史性突破，2026年3月获FDA批准。复发难治阶段，国产PD-1抑制剂（信迪利单抗、卡瑞利珠单抗、替雷利珠单抗、派安普利单抗）早已在国内形成可及性优势。 4. T细胞淋巴瘤：国产创新药的突围 外周T细胞淋巴瘤（PTCL）长期缺乏突破性药物，近两年国产原研实现连续突破： SKILL 1戈利昔替尼（迪哲医药，JAK1抑制剂） 基于JACKPOT8研究（ORR 44.3%，CR率23.9%），2024年6月获NMPA附条件批准用于复发难治PTCL，是全球首个且唯一获批PTCL适应症的JAK1抑制剂，并获FDA快速通道资格推进国际注册。 SKILL 2西达本胺（微芯生物，HDAC抑制剂） DEB研究（III期，2024年ASCO最新突破摘要口头报告）显示，西达本胺联合R-CHOP一线治疗MYC/BCL-2双表达DLBCL，CR率73.0%对61.8%（P=0.014），24个月EFS率58.9%对46.2%；2024年4月获NMPA批准该一线适应症，获2025版CSCO指南I级推荐（1A类证据）。 国内企业代表性在研项目 迪哲医药的戈利昔替尼（高瑞哲®）——全球首个获批PTCL的JAK1抑制剂，从机制源头切入T细胞淋巴瘤（见上文）。 微芯生物的西达本胺（爱谱沙®）——PTCL二线获批十年后，以DEB研究攻入DLBCL一线，实现“老药新用”的证据升级。 恒瑞医药/璎黎药业的林普利塞——PI3Kδ抑制剂，2022年获批用于复发难治FL，是国产首个淋巴瘤PI3K抑制剂。 百济神州的泽布替尼——2024年3月获FDA批准联合奥妥珠单抗用于R/R FL，成为首个获FDA批准FL适应症的中国原研BTK抑制剂。 02 PART 慢性淋巴细胞白血病与BTK/BCL-2通路：从迭代到降解 CLL · BTK / BCL-2 PATHWAY CLL/SLL是BTK抑制剂最大的适应症战场，已完成三代更迭：第一代伊布替尼（不可逆共价）；第二代泽布替尼、阿可替尼（选择性更高，ALPINE研究头对头证实泽布替尼PFS优效于伊布替尼）；第三代匹妥布替尼（非共价，BRUIN研究确立共价BTK抑制剂失败后的挽救地位，已在中国获批用于R/R套细胞淋巴瘤）。下一代方向是BTK降解剂（如百济神州的BGB-16673，I期已在多重经治CLL中显示活性），旨在同时克服耐药突变。 BCL-2抑制剂是另一条核心通路。维奈克拉（联合奥妥珠单抗或BTK抑制剂）确立固定疗程模式后，国产第二代BCL-2抑制剂密集撞线：亚盛医药的利沙托克拉（lisaftoclax）2025年7月获NMPA附条件批准用于BTK抑制剂经治的R/R CLL/SLL，是全球第二个上市的BCL-2抑制剂，关键注册II期达到预设ORR终点且研究中未发生肿瘤溶解综合征；百济神州的索托克拉（sonrotoclax）NDA于2025年4月获CDE受理并纳入优先审评，其联合泽布替尼一线治疗CLL的早期研究ORR达100%，正在III期中验证“国产双剑合璧”的固定疗程方案。 国内企业代表性在研项目 百济神州的泽布替尼（百悦泽®）——ALPINE研究优效证据加持下，2025年第一季度全球销售额56.92亿元（同比增长63.7%），稳居全球BTK抑制剂销量第一，销售峰值预期超50亿美元。 亚盛医药的利沙托克拉（利生妥®）——中国首个、全球第二个BCL-2抑制剂（见上文），联合阿可替尼方案ORR达98%（2024年ASH），正向一线与更多血液瘤拓展。 百济神州的索托克拉+BGB-16673——前者有望成为第二款国产BCL-2抑制剂，后者为全球进度领先的BTK降解剂（CDAC），构成CLL领域的纵深管线。 诺诚健华的奥布替尼——2023年获批用于复发难治边缘区淋巴瘤（MZL），为国内该适应症首个获批的BTK抑制剂。 03 PART 急性白血病：menin抑制剂开创新时代，免疫治疗前移 ACUTE LEUKEMIA · MENIN ERA 1. AML：分子分型驱动的口服靶向时代 “7+3”化疗与维奈克拉联合阿扎胞苷（VIALE-A研究）之后，急性髓系白血病（AML）最重要的突破来自menin抑制剂——通过阻断menin-KMT2A相互作用，靶向HOXA9/MEIS1过表达驱动的白血病亚型（KMT2A重排约占10%、NPM1突变约占30%，既往复发难治后中位OS仅约6个月）： TOOL 药物revumenib（Revuforj） 2024年11月获FDA批准用于KMT2A重排急性白血病，成为史上首个menin抑制剂；2025年10月扩展至NPM1突变AML（CR+CRh率23.1%）。 TOOL 药物ziftomenib 2025年11月获FDA批准用于NPM1突变AML。 应清醒认识到，menin抑制剂单药活性有限（CR/CRh率20%～30%），联合强化疗或低强度方案的III期研究正在进行；bleximenib、enzomenib等后续分子已进入后期临床，国内和黄医药的HMPL-506等亦在推进。另一面，CD47单抗magrolimab的两项III期（ENHANCE-2/3）因无效相继终止，提示新靶点开发的失败风险同样真实存在。 2. ALL：免疫治疗进入一线，CAR-T补上成人短板 贝林妥欧单抗（E1910研究）：在标准化疗基础上加入贝林妥欧单抗巩固，3年OS率84.8%对69%（HR=0.42），5年OS率82.4%对62.5%；2024年6月获FDA批准用于Ph阴性B-ALL一线巩固，双特异性抗体由此从挽救治疗进入一线，成为ALL领域近十年最重要的范式转变。 奥比卡妥品（obe-cel，Aucatzyl）：FELIX研究3个月内CR率42%，中位缓解持续14.1个月；2024年11月获FDA批准用于成人R/R B-ALL，为成人患者提供新的CAR-T选择。 Ph+ ALL：第三代BCR-ABL1抑制剂普纳替尼（PhALLCON研究）确立一线地位；国产奥雷巴替尼正通过POLARIS系列III期向一线联合、维持及与CAR-T序贯方向拓展。 国内企业代表性在研项目 亚盛医药的奥雷巴替尼（耐立克®）——中国首个且唯一获批的第三代BCR-ABL1抑制剂（2021年，T315I突变CML）；2024年6月与武田达成独家选择权协议（含最高约13亿美元付款），海外开发由武田主导；POLARIS-1（一线Ph+ ALL联合化疗）、POLARIS-2（CML，获FDA许可）等注册III期推进中。 合源生物的纳基奥仑赛——CD19 CAR-T，2023年11月获NMPA批准用于成人R/R B-ALL，是国内首个白血病领域的CAR-T产品。 和黄医药的HMPL-506——国产menin抑制剂，处于I期临床，跟进AML分子分型治疗方向。 04 PART 多发性骨髓瘤：BCMA靶向全面前移 MULTIPLE MYELOMA · BCMA ADVANCE 1. 一线与冒烟型：四联奠基、干预前移 PERSEUS研究（达雷妥尤单抗+VRd，发表于《新英格兰医学杂志》2024）确立了适合移植新诊断MM的四联诱导标准；AQUILA研究进一步将达雷妥尤单抗单药推向高危冒烟型骨髓瘤（2025年5月ODAC以6:2支持其获益-风险），“等待观察”的传统策略首次被动摇。 2. BCMA ADC的“复活”：belantamab mafodotin 该药曾因验证性研究DREAMM-3失败于2022—2024年在美欧撤市，凭借DREAMM-7/8两项III期强势回归：BVd方案中位PFS 36.6个月对13.4个月（HR=0.41），死亡风险降低42%（HR=0.58），3年OS率74%对60%（发表于《新英格兰医学杂志》2024及《柳叶刀·肿瘤学》2025）。2025年在英国、日本、欧盟相继获批；美国虽经ODAC以5:3质疑其眼部毒性（任意级别发生率约92%、3/4级77%），FDA仍于2025年10月23日批准其用于三线及以上（附黑框警告与REMS眼毒性监测计划）；2026年7月获NMPA批准。这一“撤市—重生”案例，是联合方案设计与风险管理重塑药物命运的经典样本。 3. BCMA/GPRC5D双抗与CAR-T：缓解深度竞赛 双特异性抗体：特立妥单抗、埃纳妥单抗（BCMA×CD3）与塔奎妥单抗（GPRC5D×CD3）已在四线后确立地位（ORR 60%～70%），并持续向前线推进；GPRC5D靶向的味觉异常、皮肤指甲毒性需专门管理。 CAR-T：西达基奥仑赛（cilta-cel）凭CARTITUDE-4于2024年4月获FDA批准二线治疗，2024年全球销售额9.63亿美元；新一代D-Domain结构CAR-T（anito-cel）注册II期iMMagine-1研究ORR达96%、CR/sCR率74%、MRD阴性率95%，且迄今未观察到迟发性神经毒性（帕金森样症状），BLA已获受理（PDUFA日期2026年12月23日）；吉利德2026年2月宣布以约78亿美元收购Arcellx，创下细胞治疗领域又一重磅交易。 国内企业代表性在研项目 驯鹿生物/信达生物的伊基奥仑赛（福可苏®）——2023年6月获NMPA批准，是中国首个、全球首个全人源BCMA CAR-T，免疫原性低、体内存续时间长。 科济药业的泽沃基奥仑赛（赛恺泽®）——2024年3月获NMPA批准，为国产第二款BCMA CAR-T。 传奇生物的西达基奥仑赛（与强生合作）——国产原研出海最成功的CAR-T：2022年中美获批，二线适应症2024年获批，正向一线III期（CARTITUDE-5/6）推进。 先声药业/先声再明的SIM0500——GPRC5D×BCMA×CD3三特异性抗体，2025年1月与艾伯维达成许可选择协议（首付款外加最高10.55亿美元里程碑），是国产多特异性抗体出海的代表作，中美I期临床进行中。 05 PART 细胞治疗：从体外制备到体内生成 CELL THERAPY · IN VIVO CAR-T 1. 国产CAR-T全景与可及性突破 截至2026年7月，国内已有8款CAR-T获批上市：复星凯特的阿基仑赛（2021，国内首个）、药明巨诺的瑞基奥仑赛（2021）、驯鹿生物/信达生物的伊基奥仑赛（2023）、合源生物的纳基奥仑赛（2023）、科济药业的泽沃基奥仑赛（2024）、传奇生物的西达基奥仑赛（2022年在国内获批）、恒润达生的雷尼基奥仑赛（2025年7月，首个采用稳转细胞株病毒载体工艺获批的国产CAR-T，实现全链条国产化）、重庆精准生物的普基奥仑赛（2025）。支付端亦有突破：2025年商保创新药目录首次设立，阿基仑赛、泽沃基奥仑赛、伊基奥仑赛、纳基奥仑赛、瑞基奥仑赛5款CAR-T全部纳入，百万元级疗法的多层次支付体系开始形成。 2. 通用型与体内CAR-T（in vivo CAR-T）：下一代技术革命 异体通用型：邦耀生物的TyU19（异体CD19 UCAR-T）治疗难治性自身免疫病的研究发表于《细胞》（2024），3例患者深度缓解且无CRS、GvHD、ICANS，是全球首批经同行评审的通用型CAR-T临床证据。 体内CAR-T：直接在体内将T细胞改造为CAR-T，有望免除清淋与体外制备。INT2104（CD20，慢病毒载体）2024年10月完成全球首例给药，是首个进入人体的体内CAR-T，吉利德/Kite于2025年8月以3.5亿美元收购Interius；ESO-T01（BCMA，ENaBL慢病毒平台）首批4例骨髓瘤患者数据发表于《柳叶刀》（2025年7月），《自然·医学》（2026年3月）更新显示5例中4例客观缓解、3例严格完全缓解、可评估者第60天MRD全部阴性——阿斯利康已于2025年3月以最高10亿美元收购EsoBiotec。值得注意的是，ESO-T01所用CAR构建体来自中国企业普瑞金生物；2025年10月，吉利德/Kite与普瑞金达成国内首个体内CAR-T授权合作（1.2亿美元首付款、最高15.2亿美元里程碑）。艾伯维（21亿美元收购Capstan）、百时美施贵宝（15亿美元收购Orbital）亦已重注LNP-RNA路线，体内CAR-T成为巨头竞逐的新赛点。 3. 安全性与清醒认识 继发T细胞恶性肿瘤：2024年1月，FDA对全部已获批BCMA/CD19 CAR-T统一加注黑框警告，要求终身监测；尽管绝对发生率低、获益-风险仍支持使用，但这改变了风险沟通与随访范式。 迟发神经毒性：BCMA CAR-T（如西达基奥仑赛）可见帕金森样迟发神经毒性；新一代结构（D-Domain等）以规避该毒性为重要卖点，尚待批准证实。 TCR-T与疫苗：WT1等靶点的TCR-T及治疗性疫苗在血液肿瘤中仍处早期探索，暂无随机对照证据。 国内企业代表性在研项目 恒润达生的雷尼基奥仑赛（恒凯莱®）——2025年7月获NMPA批准用于二线以上R/R LBCL，首个稳转细胞株病毒工艺国产CAR-T，获2026版CSCO淋巴瘤指南II级推荐。 重庆精准生物的普基奥仑赛——2025年获批，使国产CAR-T总数达8款，覆盖淋巴瘤、骨髓瘤、白血病三大适应症。 普瑞金生物的体内CAR-T平台——其CAR构建体支撑全球首个BCMA体内CAR-T（ESO-T01）的人体概念验证，并与Kite达成超16亿美元合作，是体内CAR-T领域最深的国产技术输出。 邦耀生物的TyU19——通用型CAR-T从肿瘤拓展至自身免疫病，发表于《细胞》，代表国产细胞治疗的源头创新能力。 /// LAST 写在最后 清醒与展望 血液淋巴系统肿瘤的创新密度在2024—2026年达到历史新高：双特异性抗体完成从三线到二线、乃至ALL一线巩固的跨越；menin抑制剂让AML首次有了分子分型驱动的口服靶向药；BTK/BCL-2通路上，国产药物完成从跟随到并跑、个别领跑的转变（泽布替尼全球销量第一、利沙托克拉全球第二个BCL-2抑制剂）；骨髓瘤领域BCMA靶向三线并进，CAR-T二线获批后向一线挺进；体内CAR-T的初步人体数据则预示细胞治疗可能迎来“现货化”的第二次革命。 同时应保持清醒：STARGLO因人群代表性被FDA拒批，提示全球多中心研究的设计质量与区域代表性已与疗效数据同等重要；belantamab mafodotin的“复活”以92%眼部毒性为代价，疗效与毒性的天平需要精细化管理；CAR-T的黑框警告、迟发神经毒性与百万元定价，决定了其可及性仍需支付体系与技术平台（通用型、体内化）的双重突破；menin抑制剂单药缓解率有限，联合策略尚未成熟。下一阶段，双抗与CAR-T的前线序贯优化、固定疗程与MRD指导的停药策略、以及体内CAR-T的成药性验证，将是最值得关注的方向。 风险提示：本文内容仅供学术交流参考，不构成任何诊疗建议。文中研究数据均来自公开发表的文献、学术会议报告及监管机构公告，具体治疗请遵循临床指南与专科医生意见。 会康临研是由一群有着相同初心的生物医药人共同搭建的一个公益性质的临床试验项目聚合信息与咨询平台。致力于分享新的前沿的临床试验招募信息，为有需求且符合条件的患者寻找新的希望，同时能得到免费的救治。 也欢迎大家动动小手，转发给更多有需要的人，每一次转发，都是一次希望的传递！❤️❤️ 如果你觉得今天这篇有收获，欢迎**点赞、在看、转发**三连，我们下篇见。 既然看到这里了，如果觉得有用，随手点个赞、在看、转发三连吧。 点赞 在看 转发 THANKS FOR READING

Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0.17 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $16.990 Billion, an Increase of 10.2 Percent on a Reported Basis or 9.5 Percent on an Operational Basis Second-Quarter Global Net Revenues from the Immunology Portfolio Were $8.786 Billion, an Increase of 15.1 Percent on a Reported Basis, or 14.6 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $5.505 Billion; Global Rinvoq Net Revenues Were $2.525 Billion; Global Humira Net Revenues Were $756 Million Second-Quarter Global Net Revenues from the Neuroscience Portfolio Were $3.228 Billion, an Increase of 20.3 Percent on a Reported Basis, or 19.8 Percent on an Operational Basis; Global Vraylar Net Revenues Were $1.071 Billion; Global Botox Therapeutic Net Revenues Were $1.042 Billion; Combined Global Ubrelvy and Qulipta Net Revenues Were $742 Million; Global Vyalev Net Revenues Were $256 Million Second-Quarter Global Net Revenues from the Oncology Portfolio Were $1.650 Billion, a Decrease of 1.5 Percent on a Reported Basis, or 2.4 Percent on an Operational Basis; Global Venclexta Net Revenues Were $771 Million; Global Imbruvica Net Revenues Were $532 Million; Global Elahere Net Revenues Were $211 Million Second-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.282 Billion, an Increase of 0.3 Percent on a Reported Basis, or a Decrease of 0.9 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $728 Million; Global Juvederm Net Revenues Were $245 Million Announced Definitive Agreement to Acquire Apogee Therapeutics, Deepening AbbVie's Immunology Portfolio Updates 2026 Adjusted Diluted EPS Guidance Range from $13.91 - $14.11 to $13.87 - $14.07; Now Includes a $0.14 per Share Dilutive Impact Related to the Proposed Acquisition of Apogee Therapeutics, Which is Anticipated to Close in the Third Quarter of 2026; Includes an Unfavorable Impact of $0.58 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2026 NORTH CHICAGO, Ill., July 31, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2026. "AbbVie delivered another excellent quarter, marked by outstanding execution and pipeline advancement. We also announced the proposed acquisition of Apogee Therapeutics, which strengthens our ability to deliver innovative medicines to patients, bolsters our immunology leadership and creates significant shareholder value," said Robert A. Michael, chairman and chief executive officer, AbbVie. "Based on our substantial momentum, AbbVie's long-term outlook remains very strong." Second-Quarter Results Worldwide net revenues were $16.990 billion, an increase of 10.2 percent on a reported basis, or 9.5 percent on an operational basis. Global net revenues from the immunology portfolio were $8.786 billion, an increase of 15.1 percent on a reported basis, or 14.6 percent on an operational basis. Global Skyrizi net revenues were $5.505 billion, an increase of 24.4 percent on a reported basis, or 24.0 percent on an operational basis. Global Rinvoq net revenues were $2.525 billion, an increase of 24.5 percent on a reported basis, or 23.7 percent on an operational basis. Global Humira net revenues were $756 million, a decrease of 35.9 percent on a reported basis, or 36.1 percent on an operational basis. Global net revenues from the neuroscience portfolio were $3.228 billion, an increase of 20.3 percent on a reported basis, or 19.8 percent on an operational basis. Global Vraylar net revenues were $1.071 billion, an increase of 18.9 percent. Global Botox Therapeutic net revenues were $1.042 billion, an increase of 12.2 percent on a reported basis, or 11.6 percent on an operational basis. Global Ubrelvy net revenues were $392 million, an increase of 16.0 percent on a reported basis, or 15.9 percent on an operational basis. Global Qulipta net revenues were $350 million, an increase of 30.9 percent on a reported basis, or 30.3 percent on an operational basis. Global Vyalev net revenues were $256 million. Global net revenues from the oncology portfolio were $1.650 billion, a decrease of 1.5 percent on a reported basis, or 2.4 percent on an operational basis. Global Venclexta net revenues were $771 million, an increase of 11.6 percent on a reported basis, or 9.6 percent on an operational basis. Global Imbruvica net revenues were $532 million, a decrease of 29.4 percent. Global Elahere net revenues were $211 million, an increase of 33.1 percent on a reported basis, or 31.8 percent on an operational basis. Global net revenues from the aesthetics portfolio were $1.282 billion, an increase of 0.3 percent on a reported basis, or a decrease of 0.9 percent on an operational basis. Global Botox Cosmetic net revenues were $728 million, an increase of 5.2 percent on a reported basis, or 3.4 percent on an operational basis. Global Juvederm net revenues were $245 million, a decrease of 6.0 percent on a reported basis, or 6.6 percent on an operational basis. On a GAAP basis, the gross margin ratio in the second quarter was 74.7 percent. The adjusted gross margin ratio was 84.7 percent. On a GAAP basis, selling, general and administrative (SG&A) expense was 21.4 percent of net revenues. The adjusted SG&A expense was 21.0 percent of net revenues. On a GAAP basis, research and development (R&D) expense was 13.8 percent of net revenues. The adjusted R&D expense was 13.6 percent of net revenues. Acquired IPR&D and milestones expense was 1.7 percent of net revenues. On a GAAP basis, the operating margin ratio in the second quarter was 37.9 percent. The adjusted operating margin ratio was 48.3 percent. Net interest expense was $679 million. On a GAAP basis, the tax rate in the quarter was 15.5 percent. The adjusted tax rate was 14.7 percent. Diluted earnings per share (EPS) in the second quarter was $2.03 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.65. These results include an unfavorable impact of $0.17 per share related to acquired IPR&D and milestones expense. Recent Events AbbVie and Apogee Therapeutics announced a definitive agreement under which AbbVie will acquire Apogee and its diverse pipeline of clinical-stage candidates in development across inflammatory and immunological diseases. The proposed acquisition includes zumilokibart (APG777), a late-stage, half-life extended monoclonal antibody targeting IL-13 for atopic dermatitis (AD), as well as APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP) in asthma. The acquisition holds potential for substantial shareholder value creation, with mega-blockbuster peak sales potential across Apogee's pipeline of assets, and is expected to close in the third quarter of 2026. The transaction values Apogee at a total equity value of approximately $10.9 billion. Additional information on the transaction can be found at investors.abbvie.com. AbbVie announced the U.S. Food and Drug Administration (FDA) and the European Commission (EC) approved Skyrizi (risankizumab) for the treatment of children six years of age and older with moderate to severe plaque psoriasis. The FDA also approved Skyrizi for pediatric use in psoriatic arthritis. These approvals were supported by data from Phase 3 OptIMMize clinical trial program. AbbVie announced the EC approved Rinvoq (upadacitinib) for the treatment of adult and adolescent patients with non-segmental vitiligo. With this approval, Rinvoq is the first systemic medication approved in the European Union (EU) for patients with non-segmental vitiligo. This approval is supported by data from the Phase 3 Viti-Up clinical program, in which Rinvoq met both co-primary endpoints, with statistically significant and clinically meaningful improvements in total body and facial repigmentation at week 48, as well as key ranked secondary endpoints. AbbVie announced the EC approved Rinvoq for the treatment of adult and adolescent patients with severe alopecia areata. This approval is supported by data from the Phase 3 UP-AA clinical program, in which Rinvoq met the primary endpoint of severity of alopecia tool score ≤ 20 as well as key secondary endpoints, including improvements in eyebrows and eyelashes, at week 24. At the 2026 Digestive Disease Week (DDW) Annual Meeting, AbbVie presented new data across its gastroenterology portfolio, including 18 abstracts in Crohn's disease (CD) and ulcerative colitis (UC). Presentations included real-world evidence and long-term findings that reinforced the efficacy, safety profile and durability of Skyrizi and Rinvoq in inflammatory bowel diseases (IBD). AbbVie announced the EC approved Aquipta (atogepant) for the acute treatment of migraine in adults with or without aura. This approval marks the second indication for Aquipta in the EU, where it is now approved as both an acute treatment option for migraine attacks and as a preventive treatment option for adults with chronic or episodic migraine who experience at least four migraine days per month. The approval is supported by data from the Phase 3 ECLIPSE trial, which showed that Aquipta resulted in statistically significant pain freedom at two hours versus placebo during the first migraine attack, with sustained pain freedom from 2 to 48 hours and a clinically meaningful and consistent effect across multiple migraine attacks. AbbVie announced the FDA approved Decnupaz (pivekimab sunirine) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive hematologic malignancy. Decnupaz is the first antibody-drug conjugate (ADC) approved for BPDCN that is initiated in an outpatient setting and marks AbbVie's first ADC approved for blood cancer. The approval is supported by data from the Phase 1/2 CADENZA trial, in which newly diagnosed patients with BPDCN treated with Decnupaz demonstrated clinically meaningful and durable responses. AbbVie announced the EC authorized an expanded label for Venclyxto (venetoclax) to include use in combination with acalabrutinib and use in combination with Imbruvica (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The authorization provides an all-oral, fixed-duration, chemotherapy-free treatment option for patients with CLL and supports the potential for time off treatment. The expanded label is supported by data from the Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial. AbbVie announced the EC granted marketing authorization for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE FL-1 trial, in which fixed-duration Tepkinly plus R2 achieved statistically significant improvement of progression-free survival (PFS) and overall response rates (ORR) compared to R2, with approximately three out of four patients achieving a complete response (CR). This approval marks the first bispecific-based therapy approved in Europe for the treatment of R/R FL in the second-line setting, offering patients a chemotherapy-free option. Tepkinly/Epkinly is being co-developed by AbbVie and Genmab. AbbVie announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of Epkinly (epcoritamab) and lenalidomide, compared to rituximab plus gemcitabine plus oxaliplatin in adult patients with R/R diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of therapy. In the trial, the chemotherapy-free combination of Epkinly plus lenalidomide demonstrated statistically significant and clinically meaningful improvement in PFS. The safety profile of Epkinly when administered in combination with lenalidomide was consistent with the known safety profiles of the individual agents. At the American Society of Clinical Oncology (ASCO) Annual Meeting, AbbVie announced new data demonstrating the breadth and momentum of its next-generation oncology pipeline. Presentations highlighted the potential of AbbVie's novel topoisomerase 1 inhibitor–based ADC and T‑cell engager platforms within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer (SCLC), platinum-resistant ovarian cancer (PROC) and multiple myeloma (MM). At the European Hematology Association (EHA) 2026 Congress, AbbVie presented data that reinforced its leadership and commitment to ongoing research to improve outcomes for people living with blood cancers. Featured data from AbbVie's blood cancer portfolio and pipeline included 21 oral and poster presentations, which highlighted etentamig (ABBV-383), Epkinly and Decnupaz. The presentations also showcased Venclexta (venetoclax) data, including a final analysis of the Phase 3 CLL14 trial which demonstrated that after a median follow-up of 9.2 years, treatment with Venclexta plus obinutuzumab resulted in superior PFS compared to treatment with obinutuzumab plus chlorambucil in previously untreated CLL. Allergan Aesthetics announced the FDA approved Skinvive by Juvederm as the first hyaluronic acid injectable indicated to reduce neck lines for the improvement of neck appearance in adults over the age of 21. This approval is supported by a randomized, multicenter, evaluator-blinded, controlled pivotal clinical study in which participants treated with Skinvive by Juvederm saw a clinically significant improvement in neck lines at one month. This approval represents the second FDA-approved indication for Skinvive by Juvederm, which is also approved to improve skin smoothness of the cheeks in adults. Allergan Aesthetics announced the EC and Health Canada approved Boey (trenibotulinumtoxinE) as the first rapid-onset, short-duration neurotoxin for the temporary improvement of moderate to severe glabellar lines in adults. These approvals are supported by data from two Phase 3 clinical trials, in which Boey demonstrated rapid onset of action as early as eight hours after administration and observed efficacy duration of two to three weeks, with treatment-emergent adverse events similar to placebo. AbbVie announced the EC approved Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection in adults and children aged 3 years and older. This approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed and makes Maviret the only treatment approved in the EU for both acute and chronic HCV infection. Full-Year 2026 Outlook AbbVie is updating its adjusted diluted EPS guidance to include the impact of the proposed Apogee Therapeutics acquisition, which is expected to be $0.14 dilutive in 2026, based upon an anticipated close in the third quarter of this year. This dilution is partially offset by $0.10 of overperformance. As a result, AbbVie is updating its adjusted diluted EPS guidance range for the full year 2026 from $13.91 - $14.11 to $13.87 - $14.07, reflecting a change of $0.04 at the midpoint. The company's 2026 adjusted diluted EPS guidance includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2026. This guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2026, as both cannot be reliably forecasted. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube. Conference Call AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss our second-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central Time. Non-GAAP Financial Results Financial results for 2026 and 2025 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with generally accepted accounting principles in the United States (GAAP) and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the proposed acquisition of Apogee Therapeutics, Inc. ("Apogee"), including the possibility that such acquisition may not be consummated on the anticipated timeframe or at all, risks related to the ability to realize the anticipated benefits of the proposed acquisition on the anticipated timeframe or at all, risks that the costs to consummate the acquisition or to obtain the anticipated benefits of the proposed acquisition could be greater than expected, the failure to obtain applicable regulatory or Apogee stockholder approval in a timely manner or otherwise, the risk that an event occurs that could give rise to the right of AbbVie or Apogee to terminate the merger agreement, risks related to the ability of AbbVie and Apogee to successfully integrate the businesses and the possibility that such integration may be more difficult, time consuming or costly than expected, risks that the proposed acquisition disrupts Apogee's or AbbVie's current plans and operations and makes it more difficult to maintain business and operational relationships, the diversion of management's attention from ongoing business operations and opportunities due to the proposed transaction, negative effects of the consummation of the proposed acquisition on business or employee relationships or the market price of AbbVie's common stock and/or operating results, significant transaction costs, the assumption of unknown liabilities, the risk of litigation and/or regulatory actions related to the proposed acquisition, the risk that zumilokibart (APG777) or other Apogee pipeline assets may not demonstrate the anticipated success, safety, or efficacy in ongoing or future clinical trials, the risk that positive interim clinical trial results for zumilokibart (APG777) may not be predictive of results in later-stage or larger clinical trials, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to AbbVie's industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, tariffs and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's and Apogee's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information; and Item 1A, "Risk Factors," of Apogee's most recently filed Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and in other documents that Apogee subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. SOURCE AbbVie 21% more press release views with Request a Demo